- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00114920
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
February 16, 2007 updated by: Graceway Pharmaceuticals, LLC
A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.
A second purpose is to evaluate the safety of the drug.
Study Overview
Study Type
Interventional
Enrollment
88
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Indiana
-
Evansville, Indiana, United States, 47713
- Welborn Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of common warts
- Two forms of birth control
Exclusion Criteria:
- Pregnant or breast feeding
- Other types of wart(s), ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Clearance of treated common wart(s)
|
Secondary Outcome Measures
Outcome Measure |
---|
Partial clearance of treated common wart(s)
|
Wart recurrence
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2004
Study Registration Dates
First Submitted
June 20, 2005
First Submitted That Met QC Criteria
June 20, 2005
First Posted (Estimate)
June 21, 2005
Study Record Updates
Last Update Posted (Estimate)
February 19, 2007
Last Update Submitted That Met QC Criteria
February 16, 2007
Last Verified
November 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1508-RESI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Warts
-
RXi Pharmaceuticals, Corp.UnknownPlantar Warts | Common Warts | HPV (Human Papillomavirus) | Periungual WartsUnited States
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Maruho Co., Ltd.CompletedCutaneous Common WartsUnited States
-
Karo Pharma ABCompletedPlantar Wart | Common WartPoland
-
Nielsen BioSciences, Inc.Recruiting
-
Assistance Publique - Hôpitaux de ParisRecruitingPalmar or Plantar WartsFrance
-
Swiss Footcare Laboratories - Poderm ProfessionalRecruitingWarts | Plantar Wart | Common WartTunisia
-
MediGeneCharité Research Organisation GmbHCompletedGenital Warts | Perianal WartsGermany
-
Novan, Inc.PPDCompletedGenital Warts | Perianal WartsUnited States
-
Combined Military Hospital AbbottabadCompletedCutaneous WartsPakistan
Clinical Trials on Resiquimod
-
Spirig Pharma Ltd.CompletedActinic KeratosisSwitzerland, Germany
-
Spirig Pharma Ltd.TerminatedNodular Basal Cell CarcinomaGermany, Switzerland
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCutaneous T Cell LymphomaUnited States
-
Graceway Pharmaceuticals, LLCCompleted
-
Graceway Pharmaceuticals, LLCCompleted
-
Graceway Pharmaceuticals, LLCCompleted
-
Graceway Pharmaceuticals, LLCCompleted
-
Graceway Pharmaceuticals, LLCCompleted
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of British ColumbiaCompletedInfluenza Vaccination in SeniorsCanada